Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Overview
Date Founded

2011

Headquarters

60 LEVERONI COURT, NOVATO, CA, 94949

Type of Company

Public

Employees (Worldwide)

610

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Contact Data
Trying to get in touch with decision makers at Ultragenyx Pharmaceutical, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Chief Operating Officer

General Counsel & Executive Vice President

Chief Commercial Officer & Executive Vice President

Chief Business Officer & Executive Vice President

Chief Medical Officer & Executive Vice President

Vice President & Controller

Chief Quality Operations Officer & Executive Vice President, Translational Sciences

Chief Technical Operations Officer & Executive Vice President

Board of Directors

Former President & Chief Executive Officer at InterMune, Inc.

Co-Founder at Seattle Genetics, Inc.

President & Chief Executive Officer at H. Lundbeck A/S

Senior Advisor, Finance at Crinetics Pharmaceuticals, Inc.

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Former Senior Vice President-Corporate Development & Strategy at Theravance Biopharma, Inc.

Founder, President & Chief Executive Officer at Ultragenyx Pharmaceutical, Inc.

Former Vice President & General Manager-European Operations at BioMarin Pharmaceutical, Inc.

President, Chief Executive Officer & Director at Coda Biotherapeutics, Inc.

Paths to Ultragenyx Pharmaceutical, Inc.
Potential Connections via
Relationship Science
You
Ultragenyx Pharmaceutical, Inc.
Owners & Shareholders
Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm is a multi strategy investor that manages portfolios of equity and fixed-income investments for institutional and private clients. Their strategies include core international/emerging market equities; international equity; international small- and mid-cap equity; balanced/asset allocation; managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Details Hidden

Alkeon Capital Management invests principally, but not solely, in long or short positions of publicly-traded and private companies in global markets on behalf of the funds it manages. They provides advisory or sub-advisory services to its clients using the general strategy except that (a) the Alkeon Growth Funds, the OAM Funds, ALPRO Growth, MS UCITs and the Insurance Series primarily invest in long and short positions of global growth stocks; (b) the Alkeon Select Funds and the Alkeon Capital Partners Fund invest primarily in long positions of global growth stocks; and (c) the Alkeon Asia Growth Funds invest primarily in long and short positions of global growth stocks based in the Asia Pacific region. Alkeon Capital Management employs a bottom-up, fundamentally driven, research-intensive approach to investing. On the long side, their investment program focuses on investing in the equity securities of companies that Alkeon believes are well positioned to benefit from demand for their products or services, including companies that can innovate or grow rapidly relative to their peers in their markets. On the short side, Alkeon Capital Management may affect short sales of securities when it believes that the market price of a security is above its estimated intrinsic or fundamental value. This analytical process involves the use of valuation models, review and analysis of published research, and, in some cases, discussions with industry experts and company visits. Alkeon also takes into account economic and market conditions.

Details Hidden

RSCM applies a research-intensive, fundamental approach to investing the funds across multiple healthcare subsectors, with a focus on allocating capital to the highest conviction ideas. The firm's investment process leverages a long-term horizon, seeking to take advantage of the healthcare sector's inherent volatility to increase position sizes over time. The funds RSCM provides investment advisory services to are permitted to make a limited amount of investments in private companies and may make investments in companies outside of healthcare-related industries, as the firm determines to be appropriate for the funds' overall portfolio balance and long-term investment strategy.

Recent Transactions
Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. purchases Dimension Therapeutics, Inc.

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Escrow Agent

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Co-Chairman, Life Sciences Practice Group

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Professional

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Fenwick & West LLP

Clients

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$3.2B
Total Enterprise Value
$1.7B
Earnings Per Share
$-3.97
Revenue
$51.5M
Net Profit
$-198M
EBITDA
$-352M
EBITDAMargin
-683.24%
Total Debt
$0
Total Equity
$609M
Enterprise Value Sales
33.1x
TEVNet Income
-8.62x
Debt TEV
0x
Investors
Details Hidden

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Details Hidden

TPG Biotech is a life science venture capital platform of TPG Capital. TPG Biotech focuses on therapeutics, medical devices, and healthcare services. By leveraging TPG''s global network to support portfolio companies, TPG Biotech provides access to opportunities and operational experts from other platforms. They target investments globally with a particular focus on opportunities in North America & Asia Pacific, and provides financing for early & later stage capital requirements.

Details Hidden

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.

Suppliers
Kyowa Kirin Co., Ltd. Chemicals | Tokyo, TY

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, OS

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

IOI Corp. Bhd. Chemicals | Putrajaya, WP

IOI Group's formation years were associated with real estate when it forayed into property development in 1982 followed by Oil Palm plantations in 1985. Today, IOI Group is internationally known as a leading global integrated palm oil player with operations stretching the entire palm value chain from seedlings to plantations to crop oil extraction to diverse value-added manufacturing across major continents - serving global markets in more than 65 countries. Close to its home-base in Malaysia, the Group is also prominently known as one of the leading property developer with significant investment holdings of prime real-estates. IOI Group employs more than 30,000 personnel of more than 23 different nationalities in 15 countries.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ultragenyx Pharmaceutical, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ultragenyx Pharmaceutical, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ultragenyx Pharmaceutical, Inc..